Effect of Qihuang Yishen Decoction on Serum Lp-PLA2 and VEGF in Chronic Kidney Disease Patients with Spleen-kidney Deficiency Syndrome
Objective To investigate the therapeutic effect of Qihuang Yishen decoction on chronic kidney disease(CKD)patients with spleen and kidney deficiency syndrome and the intervention effect on serum lipoprotein-associated phos-pholipase A2(Lp-PLA2)and vascular endothelial growth factor(VEGF).Methods From July 2022 to June 2023,80 CKD patients with spleen and kidney deficiency syndrome were selected and divided into two groups by random number table meth-od,with 40 cases in each group.The control group was treated with conventional Western medicine,and the research group was treated with Qihuang Yishen decoction for 3 consecutive months.The therapeutic effects of traditional Chinese and West-ern medicine,adverse reactions,renal function indexes[blood urea nitrogen(BUN),blood creatinine(Scr),glomerular fil-tration rate(eGFR)],TCM syndrome score,Lp-PLA2,and VEGF before and after treatment were statistically compared be-tween the two groups.Results At 1 month and 3 months after treatment,the main TCM syndrome score,secondary TCM syndrome score and total score of the research group were lower than those of the control group,and the difference was statisti-cally significant(P<0.01).BUN,Scr,eGFR,Lp-PLA2 and VEGF in the research group were lower than those in the con-trol group at 1 month and 3 months after treatment,and the differences were statistically significant(P<0.05,P<0.01).The total effective rates of the research group were95.0%(38/40)and92.5%(37/40),respectively,which were higher than those of the control group[77.5%(31/40)and 75.0%(30/40)],and the difference was statistically significant(P<0.05).There was no abnormal liver and renal function between the two groups,nor significant difference in the incidence of adverse reactions(P>0.05).Conclusion Qihuang Yishen decoction can further improve renal function,relieve symptoms,improve clinical efficacy,and regulate Lp-PLA2,VEGF and other factors in CKD patients with spleen and kidney deficiency syndrome,with high safety.
万方数据
